

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Hiroyoshi Yokoi

Page 1/5

Tuesday, January 22, 2019

ROOM 1 - MAIN ARENA 1

- 12:15 – 13:30** **“To stent or not to stent?” – Latest data on stentless and stent-based treatment approaches for femoropopliteal lesions**
MODERATOR:
Dierk Scheinert
William Gray
PANEL:
Osamu Iida
Gunnar Tepe
Hiroyoshi Yokoi
- 12:15 – 12:55 FOCUS ON NEW DATA ON DRUG-COATED BALLOONS
- 12:15 – 12:20 First time data release: Randomized trial of DCB vs. PTA: Final 3-year clinical outcomes from IN.PACT Japan
Osamu Iida
- 12:20 – 12:25 First time data release: Insights from the IN.PACT global study 3-year data: Does lesion complexity affect results?
Jos van den Berg
- 12:25 – 12:30 First time data release: Global diabetic analyses of all Lutonix DCB SFA combined trials
Koen Deloose
- 12:30 – 12:35 First time data release: COMPARE-Pilot RCT: 2-year results of a randomized comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions
Dierk Scheinert
- 12:35 – 12:40 First time data release: IN.PACT Global study 3-year outcomes for stented vs. non-stented lesions
Thomas Zeller
- 12:40 – 12:45 First time data release: Real-world experience with a paclitaxel-coated balloon for the treatment of atherosclerotic infrainguinal arteries: 24-month results of the BIOLUX P-III full cohort
Gunnar Tepe
- 12:45 – 12:50 DCB in severe Calcium: Core-laboratory analysis and perspectives from the ILLUMENATE trial series
Sean Lyden
- 12:50 – 12:55 Stellarex in real world: Interim look from the SAVER registry
Frank Vermassen

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Hiroyoshi Yokoi

Page 2/5

Tuesday, January 22, 2019

- | | |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12:55 – 13:30 | FOCUS ON NEW DATA ON DRUG-ELUTING STENTS AND DCB/IMPLANT COMBINATIONS |
| 12:55 – 13:00 | First time data release: Final 12-month results of the Zilverpass-RCT of Zilver PTX vs. bypass
Marc Bosiers |
| 13:00 – 13:05 | TOBA II Trial (Lutonix or POBA + Tack) – 1-year results
William Gray |
| 13:05 – 13:10 | First time data release: Diabetic patients treated in the IMPERIAL randomized trial comparing Eluvia and Zilver PTX stents
Stefan Müller-Hülsbeck |
| 13:10 – 13:15 | First time data release: Japanese patients treated in the IMPERIAL randomized trial comparing Eluvia and Zilver PTX stents
Osamu Iida |
| 13:15 – 13:20 | First time data release: Zilver PTX Japan 5-year results for paclitaxel-eluting stent treatment of femoropopliteal artery disease
Hiroyoshi Yokoi |
| 13:20 – 13:25 | The Illumina FIH study with a next generation DES – 12-month results
Dierk Scheinert |
| 13:25 – 13:30 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Hiroyoshi Yokoi

Page 3/5

Wednesday, January 23, 2019

ROOM 5 - GLOBAL EXPERT EXCHANGE

08:00 – 09:45 Lower limb interventions (part I) – Focus on latest information on drug-coated balloons

MODERATOR:

William Gray
Koen Deloose

PANEL:

Juan Fernando Granada Solis
Aloke Finn
Eugenio Stabile

- 08:00 – 08:25 Live case transmission from Leipzig
University Hospital Leipzig, Dep. Angiology - Live case center
- 08:25 – 08:30 Pre-clinical and histology findings from different DCBs
Raphael Coscas
- 08:30 – 08:35 First time data release: A mechanistic look at o.018 DCBs: Considerations for efficacy and durability of response
Juan Fernando Granada Solis
- 08:35 – 08:40 How DCB drug dose effects vessel healing
Aloke Finn
- 08:40 – 08:45 1-year outcome of the KANSHAS 1 study of the novel KANSHAS drug-coated balloon for treatment of femoropopliteal occlusive disease: the first-in-human study
Michael Lichtenberg
- 08:45 – 08:50 Total IN.PACT 1-year results: Clinical outcomes from All-Comers
Marianne Brodmann
- 08:50 – 08:55 Total IN.PACT 1-year results: Imaging and propensity analysis
John Laird
- 08:55 – 09:00 6-month SFA results from Levant Japan
Hiroyoshi Yokoi
- 09:00 – 09:05 Outcomes of DCB use in real world patients: 3-year clinical outcomes from the IN.PACT global study
Koen Deloose

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Hiroyoshi Yokoi

Page 4/5

Wednesday, January 23, 2019

- | | |
|---------------|-------------------------------------------------------------------------------------------------------------------|
| 09:05 – 09:10 | Ranger DCB SFA registry: 24-month full cohort analysis
Michael Lichtenberg |
| 09:10 – 09:15 | Long term results from the LegDeb registry
Eugenio Stabile |
| 09:15 – 09:20 | Cost economic evidence: what do DCB deserve? The US case example
George Adams |
| 09:20 – 09:25 | Adverse effects of Paclitaxel on arterial pathology: Are we using the right drug on our DCBs?
Ulrich Beschoner |
| 09:25 – 09:30 | 12-month data from the EFFPAC randomized clinical trial
Marcus Thieme |
| 09:30 – 09:45 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

The logo for LINC (Leipzig Interventional Network Course) features the letters 'L I N C' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Hiroyoshi Yokoi

Page 5/5

Wednesday, January 23, 2019

ROOM 5 - GLOBAL EXPERT EXCHANGE

09:45 – 10:45

JET@LINC

MODERATOR:

Giancarlo Biamino

Kazushi Urasawa

Hiroyoshi Yokoi

PANEL:

Michinao Tan

Tatsuya Nakama

Masahiko Fujihara

Daizo Kawasaki

Osamu Iida

09:45 – 09:50

Introduction

09:50 – 09:58

A review of revascularisation techniques for femoropopliteal occlusions in Japan

Michinao Tan

09:58 – 10:06

The efficacy of pedal artery revascularisation; the final frontier of lower limbs intervention

Tatsuya Nakama

10:06 – 10:14

The reconsideration of evaluation for complex SFA disease by the multidisciplinary modalities

Masahiko Fujihara

10:14 – 10:22

IVUS guided intraluminal wiring for peripheral CTO lesion

Daizo Kawasaki

10:22 – 10:30

Overview of CLI treatment evidence vs. experience

Osamu Iida

10:30 – 10:45

Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.